Anzeige
Mehr »
Login
Sonntag, 09.02.2025 Börsentäglich über 12.000 News von 685 internationalen Medien
Joe Rogan nannte dieses Unternehmen "Mind-Blowing" - und jetzt stimmt die Wall Street zu!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3EWMJ | ISIN: US8989201038 | Ticker-Symbol: PL3
Tradegate
06.02.25
10:06 Uhr
4,260 Euro
+0,120
+2,90 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
TUHURA BIOSCIENCES INC Chart 1 Jahr
5-Tage-Chart
TUHURA BIOSCIENCES INC 5-Tage-Chart
RealtimeGeldBriefZeit
4,0604,22007.02.

Aktuelle News zur TUHURA BIOSCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrTuHURA Biosciences, Inc./NV - S-4, Registration of securities, business combinations-
TUHURA BIOSCIENCES Aktie jetzt für 0€ handeln
03.01.TuHURA Biosciences, Inc./NV - 8-K, Current Report-
23.12.24TuHURA Biosciences, Inc./NV - S-8, Securities to be offered to employees in employee benefit plans-
12.12.24TuHURA to acquire Kineta in immunotherapy push12
12.12.24TuHURA Biosciences, Inc. Enters into Definitive Merger Agreement to Acquire Kineta, Inc.257Opportunistic acquisition adds Phase 2 novel checkpoint inhibitor (KVA12123) to TuHURA's late stage pipelineTargeting Phase 2a/b trial with KVA12123 in mutated NPM1 AML in 2025Cross product and technology...
► Artikel lesen
12.12.24TuHURA Biosciences, Inc./NV - 8-K, Current Report1
25.11.24TuHURA gears up for Phase 3 cancer trial in 20253
25.11.24TuHURA bereitet sich auf Phase-3-Krebsstudie im Jahr 2025 vor10
25.11.24TuHURA Biosciences, Inc. Outlines Development Pathway for Single Phase 3 Accelerated Approval Registration Trial in First Line Treatment of Advanced or Metastatic Merkel Cell Carcinoma and Provides Business Update379IFx-2.0, a first-in-class innate immune response agonist, entering single Phase 3 accelerated approval registration trial in first half of 2025 for first line treatment of Merkel Cell Carcinoma (MCC)...
► Artikel lesen
25.11.24TuHURA Biosciences, Inc./NV - 8-K, Current Report2
15.11.24TuHURA Biosciences, Inc./NV - 8-K, Current Report6
23.10.24TuHURA Biosciences, Inc.: TuHURA Biosciences Announces Webcast Replay of Panel Presentation at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC427TAMPA, FL / ACCESSWIRE / October 23, 2024 / TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 registration-stage immune-oncology company developing novel technologies to...
► Artikel lesen
22.10.24TuHURA Biosciences, Inc.: TuHURA Biosciences to Present at the Virtual Investor "New to the Street" Event395Live moderated webcast with Dr. Jim Bianco, President and Chief Executive Officer of TuHURA on Wednesday, October 30th at 4 PM ET TAMPA, FL / ACCESSWIRE / October 22, 2024 / TuHURA Biosciences, Inc....
► Artikel lesen
17.10.24TuHURA Biosciences, Inc.: TuHURA Biosciences Completes Merger Transaction with Kintara Therapeutics593Combined company will operate as TuHURA Biosciences, Inc. and advance pipeline of novel technologies to overcome resistance to cancer immunotherapyLead program entering single Phase 3 accelerated approval...
► Artikel lesen
17.10.24TuHURA Biosciences finalizes merger, sets Phase 3 trial3
17.10.24XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 17.10.2024451The following instruments on Boerse Frankfurt do have their last trading day on 17.10.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 17.10.2024ISIN NameCA0403282050 ARHT...
► Artikel lesen
16.10.24Kintara genehmigt Aktienzusammenlegung im Verhältnis 1:35 vor Fusion10
16.10.24Kintara approves 1-for-35 reverse stock split before merger2
16.10.24Kintara Therapeutics Announces Correction to Prior Announcement Regarding 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences to Close on October 18, 2024181SAN DIEGO, Oct. 16, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. ("Kintara") (NASDAQ: KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today...
► Artikel lesen
16.10.24Kintara approves reverse stock split, rebrands as TuHURA Biosciences3
Seite:  Weiter >>
59 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1